QuinStreet (QNST)
(Delayed Data from NSDQ)
$19.96 USD
-0.21 (-1.04%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $19.96 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Price, Consensus and EPS Surprise
QNST 19.96 -0.21(-1.04%)
Will QNST be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for QNST based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QNST
Are You Looking for a Top Momentum Pick? Why QuinStreet (QNST) is a Great Choice
QuinStreet (QNST) Q4 Earnings Meet Estimates
QNST: What are Zacks experts saying now?
Zacks Private Portfolio Services
GoDaddy (GDDY) Beats Q2 Earnings and Revenue Estimates
Zacks Industry Outlook Highlights GoDaddy, MakeMyTrip, QuinStreet and Asure Software
4 Internet Delivery Services Stocks to Watch Amid Industry Challenges
Other News for QNST
Insider Sale: CFO Gregory Wong Sells 41,855 Shares of QuinStreet Inc (QNST)
QuinStreet to Participate at B. Riley Consumer and TMT Conference
QuinStreet Inc (QNST) Shares Up 7.44% on Sep 9
QuinStreet: Take Profits Now As Capital Structure Deteriorates Amid High Valuation (Rating Downgrade)
Private Capital's Strategic Moves Highlight Ligand Pharmaceuticals in Q2 2024